ArticleJournal of gastroenterology2026
Stage-associated remodeling of CD169 macrophage states is linked to immune regulation in colitis-associated colorectal cancer.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColitis-associated colorectal cancer (CAC) is driven by chronic inflammation and immune dysregulation. However, how macrophage state heterogeneity is organized across different stages of CAC progression remains unclear.
methodsHere, using genetic depletion, single-cell transcriptomics, and pharmacological intervention, and analysis of human colitis-associated colorectal cancer specimens, we identify stage-associated remodeling of CD169-associated macrophage states during CAC progression.
resultsWe demonstrate that CD169 marks functionally distinct macrophage states with opposing roles: CD169-low macrophages predominate during colitis and exhibit pro-inflammatory features, whereas CD169-mid/high macrophages emerge at tumor stages, localize preferentially to para-tumor regions, and display immunosuppressive and immune-inert interaction profiles. These observations support stage-associated remodeling of CD169-associated macrophage states during CAC progression. Importantly, CD169 depletion restrains tumor growth and enhances intratumoral T cell infiltration, highlighting CD169-associated macrophages as potential therapeutic targets in inflammation-driven colorectal tumorigenesis.
conclusionsTogether, our findings reveal stage-associated remodeling of CD169-associated macrophage states during CAC progression, with distinct CD169 states exhibiting divergent immune regulatory features at different disease stages. These findings highlight the importance of considering macrophage state heterogeneity when targeting CD169-associated pathways and support further investigation of state-informed therapeutic strategies in inflammation-driven colorectal tumorigenesis.
Indexed as
Identifiers
42342977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.